%0 Journal Article
%T Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus.
%A Ye T
%A Zhou J
%A Guo C
%A Zhang K
%A Wang Y
%A Liu Y
%A Zhou J
%A Xie Y
%A Li E
%A Gong R
%A Zhang J
%A Chuai X
%A Chiu S
%J Cell Rep
%V 43
%N 6
%D 2024 Jun 25
%M 38787725
暂无%R 10.1016/j.celrep.2024.114269
%X The 2022 mpox outbreak led the World Health Organization (WHO) to declare it a public health emergency of international concern (PHEIC). There is a need to develop more effective and safer mpox virus (MPXV)-specific vaccines in response to the mpox epidemic. The mRNA vaccine is a promising platform to protect against MPXV infection. In this study, we construct two bivalent MPXV mRNA vaccines, designated LBA (B6R-A29L) and LAM (A35R-M1R), and a quadrivalent mRNA vaccine, LBAAM (B6R-A35R-A29L-M1R). The immunogenicity and protective efficacy of these vaccines alone or in combination were evaluated in a lethal mouse model. All mRNA vaccine candidates could elicit potential antigen-specific humoral and cellular immune responses and provide protection against vaccinia virus (VACV) infection. The protective effect of the combination of two bivalent mRNA vaccines and the quadrivalent vaccine was superior to that of the individual bivalent mRNA vaccine. Our study provides valuable insights for the development of more efficient and safer mRNA vaccines against mpox.